1
|
Jiao XX, Lin SY, Lian SX, Qiu YR, Li ZH, Chen ZH, Lu WQ, Zhang Y, Deng L, Jiang Y, Hu GH. The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway. Neoplasma 2020; 67:834-842. [PMID: 32386478 DOI: 10.4149/neo_2020_190805n716] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 11/06/2019] [Indexed: 11/08/2022]
Abstract
Breast cancer, especially triple-negative breast cancer, is one of the deadliest cancers in women. To date, there is a lack of a good therapeutic regimen for it. PPARγ has been reported to be a tumor suppressor and could be activated by many agonists involved in cancer inhibition. Therefore, the expression of PPARγ in breast cancer was analyzed by online software UALCAN whose data were from the TCGA database. The results revealed that the PPARγ expression was reduced in breast cancer tissues. Furthermore, the methylation in the PPARγ promoter was also assayed and the results indicated that the methylation level in the PPARγ promoter in breast cancer tissue was higher than that in normal tissue. In order to verify the methylation in promoter involved in the regulation of gene PPARγ expression, the 5'-Aza and fluorescence assays were performed and the results proved that methylation in promoter participated in gene PPARγ expression regulation. Pioglitazone, a PPARγ agonist, still was not investigated in breast cancer. Therefore, the effects of pioglitazone on breast cancer cells were tested by cell viability, scratch and transwell assays, and results indicated that the pioglitazone has the inhibition effect on the proliferation and migration of breast cancer cells by PPARγ which was correlated with the JAK2/STAT3 pathway. In order to further confirm the inhibition effect of pioglitazone on breast cancer in vivo, the nude mice model was administrated by gavage with pioglitazone. And the results indicated that pioglitazone could inhibit the growth of breast cancer in the PPARγ overexpression group in vivo. In summary, the expression of gene PPARγ was decreased in breast cancer tissues, which was correlated with its methylation in the promoter region. Moreover, pioglitazone could exert its inhibition on breast cancer proliferation and migration by the JAK2/STAT3 pathway.
Collapse
Affiliation(s)
- X X Jiao
- Baoshan branch, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - S Y Lin
- School of Life Science, Nantong University, Nantong, China
| | - S X Lian
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Y R Qiu
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Z H Li
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Z H Chen
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - W Q Lu
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Y Zhang
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - L Deng
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Y Jiang
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - G H Hu
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
2
|
Tian CX, Li L, Qiu P, Qiu YR. Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts. Br J Biomed Sci 2019; 77:24-28. [PMID: 31532353 DOI: 10.1080/09674845.2019.1666783] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- CX Tian
- Laboratory Medicine Centre, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Department of Clinical Laboratory Science, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China
| | - L Li
- Department of Clinical Laboratory Science, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China
| | - P Qiu
- Division of Nephrology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China
| | - YR Qiu
- Laboratory Medicine Centre, Nanfang Hospital, Southern Medical University, Guangzhou, China
| |
Collapse
|
3
|
Qiu YR, Zhao MY, Sun L, Yang BC, Hei KW, Du X, Li YM. Expression of IncRNA UCA1 in ovarian cancer and its clinical significance. EUR J GYNAECOL ONCOL 2017; 38:191-195. [PMID: 29953778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVES To explore the expression and clinical significance of IncRNA-UCA1 in ovarian cancer. MATERIALS AND METHODS The ex- pression of IncRNA-UCA1 in 26 ovarian cancer tissue and 16 normal and benign ovarian tissue were detected using qRT-PCR method, and the correlation of expression level with clinicopathological features were analyzed. RESULTS Higher lncRNA-UCA1 expression level were detected in ovarian cancer tissue than those in normal ovarian tissue (p < 0.05). There were significant correlations between higher expression of IncRNA-UCA1 with tumor staging (p = 0.000), histological grades (p = 0.000), peritoneal effusion (p = 0.001), and lymph node metastasis (p = 0.000), but not with age. CONCLUSION IncRNA-UCA1 may play a vital role in the metastasis of ovarian cancer and it is expected to be a potential novel biomarker and therapeutic target of ovarian cancer.
Collapse
|
4
|
Wang HX, Chu S, Li J, Lai WN, Wang HX, Wu XJ, Kang X, Qiu YR. Increased IL-17 and IL-21 producing TCRαβ+CD4−CD8− T cells in Chinese systemic lupus erythematosus patients. Lupus 2014; 23:643-54. [PMID: 24554709 DOI: 10.1177/0961203314524467] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2013] [Accepted: 01/23/2014] [Indexed: 01/06/2023]
Abstract
Background: Increased numbers of TCRαβ+CD4−CD8− T cells in the peripheral blood of systemic lupus erythematosus (SLE) patients in the United States and United Kingdom have been reported. However, the proportions of TCRαβ+CD4−CD8− T cells and their involvement in the pathogenesis of SLE in Chinese populations are yet to be determined. Methods: A total of 120 SLE patients, 38 rheumatoid arthritis (RA) patients and 43 normal control subjects were examined. The proportion of TCRαβ+CD4−CD8− T cells in the peripheral blood, Fas expression on these cells, and intracellular cytokine levels in these cells were assessed using flow cytometry. Plasma cytokine concentrations were measured using enzyme-linked immunosorbent assay. Results: The percentages of TCRαβ+CD4−CD8− T cells were increased in Chinese SLE patients, particularly in active SLE patients, correlated with decreased Fas expression on these cells. IL-17 and IL-21 levels in the blood and in TCRαβ+CD4−CD8− T cells from SLE patients were increased. Moreover, a positive correlation was evident between IL-17- and IL-21-producing TCRαβ+CD4−CD8− T cells. Conclusions: Increased TCRαβ+CD4−CD8− T cells expressing inflammatory cytokines, such as IL-17 and IL-21, may be implicated in the pathogenesis of SLE in patients. Appropriate IL-17- and/or IL-21 blockage may be utilized as a novel immunotherapeutic strategy for SLE patients.
Collapse
Affiliation(s)
- H-X Wang
- Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - S Chu
- Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - J Li
- Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - W-N Lai
- Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - H-X Wang
- Department of Laboratory Medicine, Nanyang Center Hospital, Henan, China
| | - X-J Wu
- Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - X Kang
- Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangdong, China
| | - Y-R Qiu
- Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangdong, China
| |
Collapse
|